DBVT vs. HUMA, VYGR, SGMO, TARS, AUTL, PSTX, ATRA, PROK, VECT, and GLUE
Should you be buying DBV Technologies stock or one of its competitors? The main competitors of DBV Technologies include Humacyte (HUMA), Voyager Therapeutics (VYGR), Sangamo Therapeutics (SGMO), Tarsus Pharmaceuticals (TARS), Autolus Therapeutics (AUTL), Poseida Therapeutics (PSTX), Atara Biotherapeutics (ATRA), ProKidney (PROK), VectivBio (VECT), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "biological products, except diagnostic" industry.
DBV Technologies vs.
DBV Technologies (NASDAQ:DBVT) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, community ranking, analyst recommendations, dividends, earnings and institutional ownership.
DBV Technologies currently has a consensus target price of $5.38, indicating a potential upside of 233.85%. Humacyte has a consensus target price of $5.58, indicating a potential upside of 80.69%. Given DBV Technologies' stronger consensus rating and higher possible upside, analysts clearly believe DBV Technologies is more favorable than Humacyte.
18.4% of DBV Technologies shares are owned by institutional investors. Comparatively, 13.1% of Humacyte shares are owned by institutional investors. 0.6% of DBV Technologies shares are owned by insiders. Comparatively, 25.0% of Humacyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
DBV Technologies has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500.
DBV Technologies received 389 more outperform votes than Humacyte when rated by MarketBeat users. Likewise, 59.88% of users gave DBV Technologies an outperform vote while only 27.78% of users gave Humacyte an outperform vote.
Humacyte has a net margin of 1,971.30% compared to DBV Technologies' net margin of -778.60%. DBV Technologies' return on equity of -52.54% beat Humacyte's return on equity.
In the previous week, Humacyte had 1 more articles in the media than DBV Technologies. MarketBeat recorded 4 mentions for Humacyte and 3 mentions for DBV Technologies. Humacyte's average media sentiment score of 0.15 beat DBV Technologies' score of 0.00 indicating that Humacyte is being referred to more favorably in the news media.
Humacyte has lower revenue, but higher earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.
Summary
DBV Technologies and Humacyte tied by winning 9 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DBV Technologies Competitors List
